ARS Corp (SPRY): Price-to-Projected Revenue Ratio

Corporate emblem and logo of ARS Pharmaceuticals Inc (SPRY)

The forward price-to-sales ratio for ARS Pharmaceuticals (SPRY) reflects market expectations, with the value 3.10 representing the current figure. This trend is driven by nasal adrenaline patents and strict FDA oversight. Business flexibility is maintained by outsourcing production and testing to third-party contractors. A sophisticated supplier redundancy system ensures supply stability, minimizing logistical risks.

SPRY ARS Pharmaceuticals Inc: Market Cap to Expected Sales Ratio in the range 04/28/2023 - 11/13/2026

Financial and market metric breakdowns for ARS Corp (SPRY)

- current price and projected stock value:
Stock Price ARS Pharmaceuticals, Inc.|SPRY - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value ARS Corp|SPRY - Value Adjusted for Debt and Cash
- book value of equity indicators:
Net Assets per Single Share ARS Pharmaceuticals|SPRY - Book Valuation of Business|Market Cap to Net Assets Ratio ars-pharma.com|SPRY - Aggregate Asset Value
- debt and solvency information:
Debt to Equity ARS Pharmaceuticals|SPRY - Long-Term Liabilities to Equity|Short-Term Debt to Capital ARS Pharmaceuticals|SPRY - Aggregate Debt Obligations|Debts to Book Capitalization ARS Corp|SPRY - Company Long-Term Debts|Company Short-Term Debt ARS Pharmaceuticals|Quick Liquidity ars-pharma.com
- business earnings and investment ratios data:
SPRY - Net Income|Projected Future Earnings ARS Pharmaceuticals|SPRY - P/E Multiple|Forward P/E Multiple ARS Pharma|SPRY - Price/Earnings to Growth Multiple|EV/EBITDA Multiple ARS Corp|SPRY - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months ARS Pharmaceuticals|SPRY - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months ars-pharma.com|SPRY - Net earnings per one share growth for the current year|Earnings growth forecast for next year ARS Pharmaceuticals
- sales volume and revenue indicators:
SPRY - Company Gross Revenue|Projected Sales Volume ARS Pharmaceuticals, Inc.|SPRY - Market Cap to Revenue|Forward P/S Multiple ARS Corp
Summary company analysis:ARS Pharmaceuticals, Inc. SPRY
Original product of ARS Corp

The forward P/S ratio assesses the market value of an asset relative to expected revenues, filtering out speculative noise. By analyzing the projected P/S multiple on GURU.Markets, an investor compares the market capitalization of ARS Pharmaceuticals (SPRY) with the sales potential of its innovative epinephrine nasal spray. This trend reflects market expectations regarding the commercialization of needle-free medications. The stability of this metric confirms the fundamental resilience of the business within the emergency medicine sector.

Competitors of ARS Pharmaceuticals

Forward P/S Multiple HLN (Haleon)|Forward P/S Multiple Kenvue Inc KVUE|VRNA - Price-to-Projected Revenue Ratio|Forward Price to Sales MENS (Jyong Bio)|Ligand Pharmaceuticals (LGND) - Price-to-Projected Revenue Ratio|AMRX - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple PRGO|ALVO: Forward Price to Sales|Price-to-Projected Revenue Ratio Liquidia Technologies (LQDA)|GLPG: Future Price to Revenue|Forward P/S Multiple ANIP (ANI Pharmaceuticals)|Forward Price to Sales MNKD|Amphastar Pharmaceuticals, Inc. - Forward P/S Multiple|PCRX - Forward P/S Multiple|Theravance (TBPH) - Price-to-Projected Revenue Ratio|Aquestive Corp - Forward Price to Sales|Price-to-Projected Revenue Ratio scPharmaceuticals, Inc.|Forward Price-to-Revenue Multiple Tectonic (TECX)|Forward P/S Multiple TNXP|Forward P/S Multiple sxtchina.com (SXTC)|Forward P/S Multiple EPRX (Eupraxia Pharmaceuticals Inc.)|BHST - Forward Price-to-Revenue Multiple|eXoZymes Inc - Forward P/S Multiple|Market Cap to Future Revenue Ratio Oramed Pharmaceuticals|ENTX (enterabio.com) - Forward Price-to-Revenue Multiple|MindWalk Holdings, Inc. (HYFT) - Forward P/S Multiple|Forward Price-to-Revenue Multiple ABVC|CPIX (Cumberland Corp) - Price to Expected Revenue Ratio|Forward P/S Multiple QNTM|Market Cap to Expected Sales Ratio fibrogen.com|Forward P/S Multiple TELO (Telomir Pharmaceuticals, Inc.)|RANI - Forward Price-to-Revenue Multiple|Synergy CHC Corporation - Forward P/S Multiple|RLYB - Forward P/S Multiple|lexariabioscience.com (LEXX) - Price-to-Projected Revenue Ratio|PULM (pulmatrix.com) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Pheton Holdings Limited|Aptorum (APM) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Lyra Therapeutics, Inc (LYRA)|Market Cap to Expected Sales Ratio Impact BioMedical, Inc.|Price-to-Projected Revenue Ratio TNF Pharmaceuticals, Inc. TNFA|YCBD (cbdMD Inc.) - Future Price to Revenue|PRFX - Price-to-Projected Revenue Ratio|Forward Price to Sales CYTO (Altamira Therapeutics)|LIPO (Lipella) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio OptiNose Corp (OPTN)|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals|procapsgroup.com - Future Price to Revenue|Forward P/S Multiple PTPI|QLI (Qilian International Holding Group) - Forward Price to Sales|Forward P/S Multiple SLRN (ACELYRIN, Inc.)|Forward P/S Multiple TFF Pharmaceuticals, Inc TFFP